AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Pozen's migraine drug answers pained call for new tablet.

Bioworld Financial Watch

| October 14, 2002 | Osborne, Randall | COPYRIGHT 2003 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

There may be some doubt about what's just "a bad headache" and what's a migraine, but those who suffer the latter are absolutely sure what they're feeling. Often, their initial clue is the dreaded "prodrome," a sense that the migraine is about to occur. Then begin the throbbing, pulsing pain and extreme sensitivity to light and sound, maybe with nausea and changes in vision, such as the appearance of auras.

The symptoms are distinct. But sufferers don't want to debate whether all these mean a genuine migraine. They just want the dizzying pain to go away.

Migraine headaches are less common than tension-type headaches, says the American Council for Headache Education, but they still afflict 25 million to 30 million people in the U.S., about 6 percent of all men and 18 percent of all women, or about 12 percent of the whole population.

Two-thirds or more of migraine victims are women (there's believed to be a hormonal link), and about half of the unlucky will first experience their migraines in childhood or adolescence.

The cause is unknown. Most likely, the migraine pain comes from blood vessels and nerves around the brain that swell as a result of activity in the brain…

Related articles from newspapers, magazines, journals, and more
Chapel Hill, N.C.-Based Pozen to Develop Migraine Drug with GlaxoSmithKline.
Newspaper article from: Knight Ridder/Tribune Business News June 13, 2003 700+ words
...statement. "This agreement with Pozen is the next big step in our commitment...free and back on track." Pozen has another migraine drug known as MT 300 awaiting approval...an stock analyst who covers Pozen for U.S. Bancorp Piper Jaffray...
Pozen income leaps, loss slows: All eyes turn toward FDA and approval of...
News wire article from: News & Observer (Raleigh, NC) July 27, 2007 700+ words
...Jul. 27--CHAPEL HILL -- Pozen, which is awaiting regulatory approval for a promising migraine drug, reported improved second...British drug maker AstraZeneca. Pozen developed the migraine drug with GlaxoSmithKline. The companies...
Pozen's migraine drug positive in phase III.(MT300)(Brief Article)
Newspaper article from: BioWorld Week October 14, 2002 700+ words
Pozen Inc.'s injected migraine drug, MT300, achieved its primary endpoint--sustained relief of...president of product development for Chapel Hill, N.C.-based Pozen. "This is a point that the FDA has advocated--that we go beyond...
Pozen again tries for migraine drug approval.
News wire article from: News & Observer (Raleigh, NC) August 9, 2005 700+ words
...Sabine Vollmer Aug. 9--Pozen officially began its third...approval for an experimental migraine drug, hoping to overcome obstacles...the most promising drug in [Pozen's] pipeline," said Jordan...D.C.-based investor in Pozen. In mid-April, Pozen shares...
Pozen's second migraine drug turned down by FDA.(Brief Article)
Newspaper article from: BioWorld Week June 7, 2004 700+ words
Pozen Inc.'s stock plummeted...letter from the FDA for its migraine drug MT 100. The oral drug, a...usually of the face and tongue. Pozen officials received the letter...Chapel Hill, N.C.-based Pozen. "Maybe they changed their...
FDA to take second look at Pozen's Chapel Hill, N.C.-made migraine drug.
News wire article from: Knight Ridder/Tribune Business News December 22, 2004 700+ words
...News Dec. 22--Pozen said Tuesday that...rejected experimental migraine drug, giving the Chapel...months. MT 100 was Pozen's second experimental migraine drug to be rejected by...in October 2003. Pozen appealed both rejections...
Pozen pulls plug on migraine drug.
News wire article from: News & Observer (Raleigh, NC) August 6, 2005 700+ words
...experimental migraine treatment, Pozen pulled the plug following an...2004, the FDA rejected the migraine drug because of concerns about its...and benefit of MT 100 before Pozen conducted more research on...Plachetka, chief executive of Pozen, said Friday. British regulators...
Pozen gives employees incentive for migraine drug's success.
News wire article from: Knight Ridder/Tribune Business News January 21, 2005 700+ words
...Pining for a blockbuster drug, Pozen has given employees special incentive to help an experimental migraine drug succeed. Directors on the...worthless Dec. 31, 2007, if Pozen has not received a letter from...is likely to be approved. Pozen's two other experimental...
FDA Rejects Pozen's Application for Anti-Migraine Drug.
Newspaper article from: The Herald-Sun (Durham, North Carolina) (via Knight-Ridder/Tribune Business News) October 21, 2003 700+ words
...pharmaceutical firm Pozen's application to market its anti-migraine drug MT 300, the company said Monday. Pozen's chief executive...Also on Monday, Pozen said it had received...agency about another migraine drug it is developing...
Chapel Hill, N.C.-Based Pozen Signs Deal for Marketing of Migraine Drug.
Newspaper article from: Knight Ridder/Tribune Business News September 5, 2003 700+ words
...in four months, Pozen has signed a $10...an injectable migraine drug developed by Chapel Hill-based Pozen. MT300, one of...next year. MT100, Pozen's lead drug...2004. An oral migraine drug, MT100 is projected...
For more facts and information, see all results

Source: HighBeam Research, Pozen's migraine drug answers pained call for new tablet.

©2010 Gale, a part of Cengage Learning. All rights reserved. About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA

The AccessMyLibrary advertising network includes: womensforum.com GlamFamily